At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 30 enrolled
Drug / intervention
Olanzapine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting, Unrelated to Chemotherapy or Radiation, in Advanced Cancer Patient - A Pilot, Dose-Finding Trial
In Brief
A Phase 3 clinical trial evaluating Olanzapine and Placebo for Advanced Cancer. Completed, enrolled 30 participants across 5 sites.
Detailed Summary
The purpose of this study is to evaluate the use of olanzapine for the treatment of cancer patients with chronic nausea and/or vomiting unrelated to chemotherapy or radiation in a randomized placebo-controlled pilot trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer
CountriesUnited States
CollaboratorsMayo Clinic
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartJul 2017
Primary CompletionJul 2019
Study CompletionSep 2020
TodayJul 2026
First PostedMay 2, 2017
Enrollment StartJul 12, 2017
Primary CompletionJul 12, 2019
Study CompletionSep 15, 2020
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 9.2 years ago
Interventions
Olanzapinedrug
Olanzapine is used as an anti-emetic.
Placeboother
The placebo is a non-anti-emetic.